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Malaria afflicts 300 million people worldwide, with 
over a million deaths every year. With no immediate 
prospect of a vaccine against the disease, drugs are the 
only choice to treat it. Unfortunately, the parasite has 
become resistant to most antimalarials, restricting the 
option to use artemisinins (ARTs) for effective cure. 
With the use of ARTs as the front-line antimalarials, 
reports are already available on the possible resis-
tance development to these drugs as well. Therefore, it 
has become necessary to use ART-based combination 
therapies to delay emergence of resistance. It is also 
necessary to discover new pharmacophores to eventu-
ally replace ART. Studies in our laboratory have 
shown that curcumin not only synergizes with ART as 
an antimalarial to kill the parasite, but is also 
uniquely able to prime the immune system to protect 
against parasite recrudescence in the animal model. 
The results indicate a potential for the use of ART–
curcumin combination against recrudescence/relapse 
in falciparum and vivax malaria. In addition, studies 
have also suggested the use of curcumin as an adjunct 
therapy against cerebral malaria. In this review we 
have attempted to highlight these aspects as well as 
the studies directed to discover new pharmacophores 
as potential replacements for ART. 
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CHLOROQUINE (CQ) is a wonder drug as an antimalarial 
in terms of its efficacy, minimal side effects and afforda-
bility. However, the development of widespread resis-
tance to this molecule has been one of the main reasons 
for resurgence of falciparum malaria, especially in the 
African continent. Replacement drugs such as sulphadox-
ine-pyrimethamine (SP) could not sustain for long due to 
the development of rapid resistance in the parasite. Other 
drugs such as amodiaquine, mefloquine, atovaquone, etc. 
could not fit the bill due to a variety of reasons, including 
development of cross-resistance, side effects and cost 
considerations. Quinine, despite its toxicity and reported 
resistance development, continues to be a final option. In 
this gloomy picture with around 300 million malaria 
cases and a million deaths per year, the advent of the use 
of artemisinin (ART) derivatives has given hope of  
malaria containment. However, the requirement of a  
7-day ART monotherapy has led to incomplete patient 
compliance. This together with the availability of spuri-
ous versions in the market has already raised concerns of 
possible resistance development to ART as well. This has 
led the World Health Organization (WHO) to insist on 
ART-based 3-day combination therapy to prolong the  
efficacy of this treatment and delay resistance develop-
ment. Effective implementation of this strategy, together 
with measures to contain and protect against mosquito 
bites has already led to signs of a decreasing trend in  
malaria incidence in the African continent. However,  
malaria needs a constant vigil and there is a need to deve-
lop newer ART-based combinations and perhaps, an  
alternative to ART as well. Studies in our laboratory and 
elsewhere with animal models have indicated that a com-
bination therapy with ART + curcumin can add a new 
dimension to malaria therapy in terms of its potential  
to prevent parasite recrudescence and relapse in falcipa-
rum and vivax malaria as well as to protect against  
cerebral malaria. In this review an attempt is made to 
provide an overview of the recent developments in this 
direction. 
ARTs and their mechanism of action 
ART, also known as qinghaosu, is extracted from the 
plant Artemisia annua or sweetworm wood, and Chinese 
scientists have made valuable contributions in the discov-
ery and use of this molecule for the treatment of malaria1. 
Various derivatives of artemisinin prepared by Chinese 
and other scientists with improved pharmaceutical prop-
erties include artemether, arteether, dihydroartemisinin, 
artesunate, artemisone and artelinate (Figure 1). These 
ART derivatives are essentially sesquiterpene lactone 
endoperoxides and are potent antimalarials, killing CQ- 
and SP-resistant parasites. ARTs are particularly more ac-
tive than any other antimalarial, reducing the number of 
parasites by approximately 104 per cycle2. 
 Multiple mechanisms of action of ART have been pro-
posed3. One line of thinking centres on ART interaction 
with heme-iron, generated in the food vacuole by hemo-
globin digestion. The concepts range from scission of the 
endoperoxide bridge by reduced heme-iron4, free-radical 
generation by alkylated heme adducts5, alkylating and 
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Figure 1. Structure of artemisinin and its derivatives. 
 
 
oxidizing proteins, and interacting with iron–sulphur  
centres in enzymes and lipids6,7. These studies would 
suggest that ART can alkylate a variety of proteins8. 
However, there is also a view that ART has a specific 
target, namely PfATP6, a SERCA-type calcium-ATPase9. 
Single nucleotide polymorphisms (SNPs) in the gene  
associated with decreased susceptibility to ART have 
been reported from French Guiana and Senegal, suggest-
ing causal association10. However, further analysis with 
more clinical samples has revealed a high degree of  
genetic diversity in this gene, making specific pheno-
type–genotype association rather tenuous11,12. 
 There have also been other proposals to explain the 
mechanism of action of ART. Thus, it has been suggested 
that ART may be interfering with flavoenzyme func-
tion13. Yet another study has shown that the parasite  
mitochondrion is an important direct target, if not the sole 
one14,15. It has been suggested that ART and related 
endoperoxide-containing derivatives may interact with 
the parasite electron transport chain to generate local free 
radicals to inhibit mitochondrial function, leading to 
death of the parasite. Interestingly, while yeast and parasite 
mitochondria are susceptible to this action of ART, 
mammalian mitochondria are resistant. More evidence is 
becoming available to suggest the link between hemoglo-
bin metabolism and ART action. It has been shown that 
endoperoxide antimalarials have an early effect on diges-
tive vacuole morphology, without having any effect on 
that of the endoplasmic reticulum16. Recent studies have 
shown that ART inhibits hemoglobin uptake and this 
process coupled with hemoglobin hydrolysis is required 
for potent antimalarial activity17. It is likely that ART has 
more than one site of action at the molecular level.  
ART-based combination therapies 
Despite the potent antimalarial action of ART, it suffers 
from poor pharmacokinetic properties and short half-
lives. This has necessitated the use of ART monotherapy 
for seven days, resulting in poor compliance. This  
together with the availability of sub-standard drugs in the 
market has necessitated the development of ART-based 
combination therapies (ACTs) to be used in a 3-day ther-
apy18, comprising ART together with a slowly eliminated 
companion blood-stage schizonticide. This treatment  
reduces the parasite burden by 108, leaving only a small 
fraction of the parasite burden to be abolished by the  
second drug. The ARTs also exert activity against  
gametocytes, reducing the probability of transmission. A 
meta-analysis of individual patient’s data from 16 ran-
domized trials consisting of 5948 patients that studied the 
effects of the addition of artesunate to the standard  
treatment regimen of Plasmodium falciparum malaria 
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Figure 2. Structure of partner antimalarials. 
 
 
indicated substantially reduced treatment failure, recru-
descence and gametocyte carriage19.  
 Several combinations of ART derivatives with a sec-
ond drug such as chloroquine, amodiaquine, mefloquine, 
lumefantrine, SP, piperaquine, dapsone–proguanil, atova-
quone–proguanil, etc. have been tried. However,  
WHO currently recommends the following four ART-
containing combinations: (1) artesunate + amodiaquine, 
(2) artesunate + SP, (3) artesunate + mefloquine, and (4) 
artemether + lumefantrine. In addition, evidence is avail-
able to add another combination to the list, namely dihy-
droartemisinin + piperaquine20 (Figure 2). Combination 
of artesunate + amodiaquine demonstrates a better overall 
efficacy than amodiaquine alone21. Amodiaquine is 
closely related to CQ and perhaps, acts through a similar 
mechanism of inhibiting the heme-detoxication process. 
However, the combination shows a high degree of phar-
macokinetic mismatch leading to prolonged exposure of 
parasites to low doses of amodiaquine and its active me-
tabolites, which may facilitate development of resistant 
parasites. Moreover, amodiaquine is reported to induce 
neutropenia. Amodiaquine is not currently recommended 
in India as an antimalarial because of its toxicity. Artesu-
nate + SP combination produced promising results in the 
Gambia22, though in subsequent WHO-led trials in Afri-
can children, the combination showed disappointing  
results19. Artesunate + mefloquine combination has been 
used in Thailand for almost a decade with excellent re-
sults23,24. The drug has also been tried in South America 
with success25. Despite development of resistance to  
mefloquine monotherapy, mediated by Pfmdr1 gene  
amplification, the combination has remained effective. 
The disadvantages of this combination are its cost, adverse 
drug reaction and pharmacokinetic mismatch of each 
drug. Artemether + lumefantrine (Coartem) is the only 
fixed-dose ART-containing formulation registered after 
internationally recognized guidelines and prioritized by 
WHO for therapy against CQ- and SP-resistant parasites. 
The combination appears to be safe and well tolerated26, 
though one study showed irreversible hearing impair-
ment27. It also suffers from the same disadvantage of 
pharmacokinetic mismatch and a complex 3-day regimen 
consisting of six doses at 0, 8, 24, 36, 48 and 60 h that 
may be difficult to comply. It is also considered inferior to 
the artesunate + mefloquine combination28,29. There is also 
considerable debate on the possibility of resistance de-
velopment to lumefantrine in Africa. Yet another combi-
nation that holds promise is dihydroartemisinin + 
piperaquine (Artekin)30,31. Piperaquine is a bisquinoline, 
structurally related to CQ. Pyronaridine, an acridine-type 
Mannich base, has been extensively studied in China and 
has been shown to have striking activity against P. falci-
parum. Artesunate–pyronaridine combination has shown 
excellent results in Phase III clinical trial32. An interest-
ing feature of the partner drugs is that they all seem to act 
primarily through interaction with heme/hemozoin in the 
food vacuole, generated from hemoglobin digestion. Re-
sistance is known to most of the combining partners, al-
though ACT is functional and effective. WHO has 
provided guidelines for the treatment of malaria, indicat-
ing the dose regimen and evaluation of the efficacy of 
each combination under a given set of conditions20. 
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ART + curcumin combination for malaria  
therapy 
As already indicated, a general principle in ACT is to 
have a partner drug with a longer half-life than ART, so 
that the residual parasites not cleared by ART are elimi-
nated by the partner drug. However, resistance of the 
parasite to the partner drug and concentrations of the 
partner drug below threshhold levels are issues to be dealt 
with in the long-term use of these ACTs. In this context, 
studies in our laboratory have shown that a new combina-
tion therapy with ART + curcumin is unique, with poten-
tial advantages over the known ACTs. Both the drugs 
have short half-lives and no resistance is known to cur-
cumin, a dietary component from turmeric, a widely used 
Indian spice. Interestingly, curcumin, in addition to hav-
ing a direct killing effect as an antimalarial, is also able 
to prime the immune system against Plasmodium berghei 
in a murine model, rendering the combination to act  
like a therapeutic vaccine. Thus, this combination  
has unique potential to prevent parasite recrudescence  
and relapse. It is well known that immunity in falciparum 
malaria is short-lived and vivax malaria poses problems 
of relapse even after several months. Studies in the mur-
ine model have indicated a potential for the use of 
ART + curcumin combination to prevent recrudescence 
and relapse, in addition to the known efficacy of ACTs in 
parasite clearance. These results are described in detail 
elsewhere33 and a brief summary is provided here. 
 Studies in our laboratory have established the antima-
larial activity of curcumin. Our studies had earlier shown 
that curcumin has modest antimalarial activity34. How-
ever, recent studies have claimed that oral delivery of 
curcumin bound to chitosan nanoparticles is able to com-
pletely cure Plasmodium yoelli-infected mice35. Interest-
ingly, we found that curcumin in combination with α,β-
arteether (AC treatment) was effective in preventing  
recrudescence, seen with ART monotherapy36. This study 
was carried out in mice infected with P. berghei (NK65, 
non-cerebral strain) for 24 h before drug treatment. The 
mechanism of action of AC treatment is of interest, for 
which studies were carried out over the last 5 years in 
mice infected with P. berghei (ANKA, cerebral strain) 
for 72 h before drug treatment. Thus, mice were infected 
for 72 h with P. berghei and then received a single injec-
tion of arteether alone (AE treatment, 750 μg), or along 
with three oral doses (5 mg/dose) of curcumin (AC).  
Cumulative data with around 400 animals are available. 
Infected, untreated animals died between 5 and 6 days. In 
AE treatment, recrudescence started around 20 days and 
the animals died around 23/24 days. The mortality was 
around 95%. In AC treatment, over 95% of the animals 
survived. Estimation of curcumin content in blood  
and tissues indicated a short half-life. Therefore, 
ART + curcumin represents a combination of two drugs 
with half-lives of a few hours. Thus it was of interest to 
unravel the short-term and long-term effects of curcumin 
in this regard. Real-time PCR analysis for parasite 
18SrRNA was carried out to get an accurate measure of 
parasitemia using a correlation between Ct values from 
real-time PCR and parasitemia as assessed using the 
Giemsa stain. The studies indicate that the AC treatment 
is able to clear the parasite in the blood faster than the AE 
treatment. 
 Cui et al.37 have shown that curcumin enhances reac-
tive oxygen species (ROS) generation in P. falciparum 
cultures in the concentration range 20–100 μM, and there 
is inhibition of histone acetylation. We have found that 
AC treatment is more potent than curcumin or AE in  
inhibiting hemozoin formation and enhancing ROS gene-
ration in P. berghei-infected mice33. Thus, it appears that 
the short-term effect of AC is mediated through ROS 
generation in the presence of heme iron. 
 However, parasites were not cleared from the liver or 
spleen in AE or AC treatments as assessed using RT–
PCR for parasite 18SrRNA. Thus, these exoerythrocytic 
parasites could be the reservoirs for subsequent recrudes-
cence in blood. Interestingly, in the AE treatment recru-
descence levels reached around 60% parasitemia and the 
animals died around 23/24 days after infection. In the AC 
treatment there was a transient increase in parasitemia to 
2–3%. These parasites disappeared in about 24 h, and the 
animals were healthy and survived for a life time. Blood 
from recrudescing animals after AE treatment could rein-
fect naïve animals and kill them in 5/6 days. Blood from 
recrudescing AC-treated animals did not infect naïve  
animals.  
 Thus, curcumin has a long-term priming effect on the 
immune system under these conditions. The striking  
increase in spleen mass during recrudescence in AE treat-
ment was completely prevented in AC treatment. The 
striking increase in spleen weight in AE treatment after 
an initial decrease started around 14 days. Microbial 
products, including those from the parasite are known to 
activate the innate immune pathway, leading to INFγ-
mediated protection in self-clearing parasite model or a 
surge of INFγ, leading to death of mice in the P. berghei 
(ANKA) model causing cerebral malaria. In the latter 
context, IL-10 becomes the anti-inflammatory cytokine 
offering protection. In view of the report that TLR2 ago-
nists induce IL-10 in antigen-presenting cells (APCs) and 
IL-10 is involved in antibody generation, efforts were 
made to quantify these parameters in the spleen and  
serum. On the 14th day, among the parameters tested, 
there was a striking increase in mRNA levels for TLR 2, 
IL-10 and IgG-subclass in spleen from AC-treated  
animals compared to AE-treated animals. AC treatment 
resulted in a decrease in INFγ and IL-12 mRNA levels. 
This picture was reflected in serum levels of cytokines 
and IgG-subclass antibody levels. Soon after infection 
there was an increase in INFγ as well as IL-10 levels. 
But, AC treatment resulted in a striking increase in IL-10 
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Figure 3. Model to explain the mechanism of action of arteether–curcumin (AC) combination therapy in Plasmodium berghei-infected mice. 
 
 
levels and a decrease in INFγ levels. Interestingly, there 
was an increase in almost all anti-parasite IgG-subclass 
antibody levels in the serum. Serum from recrudescing 
AC-treated animals reacted with several parasite proteins 
in the Western blot analysis, when compared to the 
preparation from AE-treated animals. All these changes 
correlated with the protection of animals during the re-
crudescence phase. In order to establish the role of TLR2 
and IL-10 in the protection offered in the AC treatment, 
experiments were carried out with knock-out animals. It 
was found that the AC-treatment was not able to offer 
protection during the recrudescence phase in TLR2–/– and 
IL-10–/– animals. IL-10 injection to AE-treated or AC-
treated TLR2–/– animals, was able to prolong survival for 
a few days33. 
 Thus, AC-treatment is able to offer protection through 
priming the immune system. This is done through the  
activation of TLR2, leading to a surge in IL-10 and anti-
parasite antibody production. Our model for the short-
term and long-term effects of AC treatment is depicted in 
Figure 3. These studies have significant implication for 
preventing recrudescence and relapse in falciparum and 
vivax malaria. As an immunomodulator, curcumin in com-
bination therapy, perhaps, has the potential to be tested in 
the case of other infections and as an adjuvant as well. 
Curcumin as an adjunct therapy against  
cerebral malaria 
It has been reported that 7% of the falciparum malaria 
cases progress to cerebral malaria (CM)38. CM is charac-
terized by neurological features, and the underlying 
pathogenesis is due to sequestration and adherence of 
parasitized erythrocytes to the brain microvasculature that 
is accompanied by over production of type-I pro-
inflammatory cytokines followed by upregulation of  
endothelial adhesion molecules39. Curcumin has profound 
anti-inflammatory activity and might exert its therapeutic 
effects in the case of CM by inhibiting NF-κB activation, 
followed by downregulation of proinflammatory cytokine 
production and expression of cytoadhesion molecules on 
endothelial cells40. With the use of the CM model in 
mice, it has been shown that curcumin is able to prevent 
CM and delay death of animals by about 10 days41. It has 
been suggested that administration of an immunomodula-
tor such as curcumin along with an anti-plasmodial drug 
would be effective in severe malaria. This is precisely the 
strategy used in our study to prevent paraite recrudes-
cence and relapse, and the underlying mechanism of anti-
inflammatory cytokine (IL-10) activation discussed  
earlier33 is likely to play an important role in combating 
CM as well. 
Future challenges 
An important issue with curcumin is its poor bioavailabil-
ity and rapid metabolism, although its efficacy against a 
variety of diseases ranging from cancer, diabetes, arthritis, 
cardiovascular and neurological diseases has been docu-
mented42. The various curcumin metabolites are given in 
Figure 4. Several attempts are underway to improve 
bioavailability through the use of preparations such as  
liposomes, phospholipid complexes, nanoparticles and 
with piperine adjuvant to inhibit curcumin metabolism43. 
However, the performance of all these curcumin prepara-
tions are yet to be assessed in humans, and most of the 
data available in the literature are with rodents. 
 More than 100 countries have moved into using ACTs, 
and this provides a challenge to produce adequate 
amounts of good quality ART in different parts of the 
globe. The present formulations available are heavily 
subsidized and it would be a challenge to sustain avail-
ability at affordable costs. Heavy demand would spur  
inferior preparations hitting the market44. Indications for 
resistance development to ACTs in the field are already 
available45,46. It also appears that in addition to the deve-
lopment of resistance to ART, inefficacy of the partner 
would also contribute to treatment failure. ARTs do  
have neurotoxicity and manifestation of the side  
effects would depend on the route of administration, lipid 
solubility and other factors. Efforts are also underway to 
prepare derivatives to reduce lipid solubility, enhance  
efficacy and decrease neurotoxicity (Table 1)44. To this 
should be added the effort to produce artemisinic acid 
through synthetic biology approach involving microbial 
production. This was achieved in the laboratory of Keasl-
ing, where it was shown that an artemisinic acid-pro-
ducing strain of Saccharomyces cerevisiae can be con-
structed by engineering the endogenous farnesyl phosphate 
pathway and expressing the Artemisia annua genes, 
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Figure 4. Structure of curcumin and its metabolites. 
 
 
Table 1. Derivatives of artemisinin 
Known artemisinin derivatives   Semi-synthetic artemisinin derivatives 
 
Artemisinin 11-Azaartemisinins 
Dihydroartemisinin Fluorinated artemisinins 
Artesunate Carbon C10 functionalized derivatives 
Artemether Carbon C15 functionalized artemisinins (including artemisitene) 
Arteether Dihydroartemisinin esters, carbonates and ethers 
Artemisinic acid from the plant Carbon C10 alkyl and aryl derivatives (including artelinate) 
  Carbon C10 amino derivatives 
 
 
amorphadiene synthase, CYP71AV1 and its redox partner. 
By engineering the bacterial, yeast and plant genes, copi-
ous amounts of the intermediate amorphadiene have been 
produced in the microbial system for eventual conversion 
to artemisinic acid that is finally converted to ART 
chemically 47. 
 What are the options when full-fledged resistance  
develops to endoperoxide compounds? At the moment the 
situation is bleak with no alternative in the basket that can 
replace ARTs. However, active research is being pursued to 
identify newer targets and molecules, as reviewed by 
Wells et al.48. One approach continues to be to improve 
upon established antimalarials such as dihydrofolate re-
ductase inhibitors or inhibitors of the electron transport 
chain such as atovaquone or 4-aminoquinolines or ami-
noalcohols. An example of such an effort is the  
design of a dual function acridone, which combines the 
heme-targeting character of acridones and a chemosensi-
tizing component that counteracts resistance to quinoline 
antimalarial drugs49. 
 Another approach is to embark on new targets based on 
knowledge of genome sequence and differential gene  
expression in different parasite stages of development. 
This may lead to molecules acting on known targets in 
the human for which a counterpart may exist in the para-
site. Structurally related compounds can be tested against 
the parasite target. Such rational design approach has led 
to molecules inhibiting enzymes of nucleoside biosynthesis 
such as DHOD50,51 transition states in adenosine deami-
nase52 and purine nucleoside phosphorylase53,54, or poten-
tial pathways in the apicoplast55. Another approach is to 
use successful targets in other therapeutic areas and then 
design molecules that can show specificity to the parasite. 
Examples of such targets are kinases, histone deacety-
lases and proteases. Another development has been high-
content screening against paraite viability in 384 and 
1536 well formats with large natural product and syn-
thetic compound libraries. A success story in this approach 
is the identification of spiroazepineindole class of com-
pounds as antimalarials with a favourable pharmacologic 
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profile from a starting library of around 12,000 com-
pounds. Lead optimization studies have led to spiroindo-
lone NITD609, showing pharmacokinetic properties 
compatible with once-daily oral dosing with single-dose 
efficacy in the rodent parasite56. The compound acts 
through a distinctly different mechanism of rapidly inhi-
biting parasite protein synthesis.  
 Most of the efforts are towards targeting the erythro-
cytic stage, and more strategies are needed to target the 
liver stage, gametocytes and the hypnozoite stage in P. 
vivax. One would like to hope that curcumin as an immu-
nomodulator would prove to be an ideal combining part-
ner with different classes of antimalarials. 
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